Theoretical Investigations on Interactions of Arylsulphonyl Indazole Derivatives as Potential Ligands of VEGFR2 Kinase.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
07 Jul 2020
Historique:
received: 26 05 2020
revised: 28 06 2020
accepted: 03 07 2020
entrez: 11 7 2020
pubmed: 11 7 2020
medline: 18 2 2021
Statut: epublish

Résumé

Vascular endothelial growth factor receptor 2 (VEGFR2) is a key receptor in the angiogenesis process. The VEGFR2 expression is upregulated in many cancers so this receptor is an important target for anticancer agents. In the present paper, we analyse interactions of several dimeric indazoles, previously investigated for anticancer activity, with the amino acids present in the VEGFR2 binding pocket. Using the docking method and MD simulations as well as theoretical computations (SAPT0, PIEDA, semi-empirical PM7), we confirmed that these azoles can efficiently bind into the kinase pocket and their poses can be stabilised by the formation of hydrogen bonds, π-π stacking, π-cation, and hybrid interactions with some amino acids of the kinase cavity like Ala866, Lys868, Glu885, Thr916, Glu917, and Phe918.

Identifiants

pubmed: 32645858
pii: ijms21134793
doi: 10.3390/ijms21134793
pmc: PMC7369845
pii:
doi:

Substances chimiques

Amino Acids 0
Antineoplastic Agents 0
Azoles 0
Indazoles 0
Ligands 0
KDR protein, human EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2 EC 2.7.10.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu
ID : 502-14-33084170-67213/2018

Références

Cell. 2019 Mar 7;176(6):1248-1264
pubmed: 30849371
J Chem Theory Comput. 2017 Jul 11;13(7):3185-3197
pubmed: 28489372
J Physiol Pharmacol. 2013 Feb;64(1):115-23
pubmed: 23568979
J Comput Chem. 2004 Oct;25(13):1605-12
pubmed: 15264254
J Chem Theory Comput. 2016 Jan 12;12(1):281-96
pubmed: 26584231
ChemMedChem. 2018 Aug 10;13(15):1490-1507
pubmed: 29863292
Bioorg Chem. 2019 Apr;85:253-273
pubmed: 30641320
Swiss Med Wkly. 2014 Nov 06;144:w14050
pubmed: 25375891
Expert Rev Anticancer Ther. 2015 Jun;15(6):677-87
pubmed: 25936222
J Med Chem. 2019 Dec 26;62(24):10927-10954
pubmed: 31419130
Eur J Med Chem. 2014 Nov 24;87:868-80
pubmed: 24576797
J Chem Inf Model. 2011 Oct 24;51(10):2778-86
pubmed: 21919503
Eur J Med Chem. 2012 Dec;58:272-80
pubmed: 23131541
Chem Rev. 2005 Aug;105(8):2999-3093
pubmed: 16092826
Pharmacol Res. 2017 Jun;120:116-132
pubmed: 28330784
Methods Enzymol. 2014;548:xi-xii
pubmed: 25399648
Pharmacol Res. 2020 Jan;151:104567
pubmed: 31770593
J Med Chem. 2018 Jan 11;61(1):140-157
pubmed: 29189002
Leukemia. 2019 Nov;33(11):2563-2574
pubmed: 31551508
J Chem Phys. 2004 Apr 15;120(15):6832-40
pubmed: 15267582
Nat Rev Mol Cell Biol. 2016 Oct;17(10):611-25
pubmed: 27461391
J Chem Phys. 2011 Nov 7;135(17):174107
pubmed: 22070292
Pharmacol Res. 2019 Jun;144:19-50
pubmed: 30877063
Inflammopharmacology. 2018 Dec;26(6):1441-1453
pubmed: 29663100
Mol Cancer Ther. 2018 Feb;17(2):455-463
pubmed: 29237803
J Comput Chem. 2010 Jan 30;31(2):455-61
pubmed: 19499576
J Physiol Pharmacol. 2017 Apr;68(2):201-207
pubmed: 28614769
J Biomol Struct Dyn. 2020 Jun;38(9):2559-2574
pubmed: 31232191
Int J Mol Sci. 2018 Apr 23;19(4):
pubmed: 29690653
Protein Eng. 1995 Feb;8(2):127-34
pubmed: 7630882
J Chem Phys. 2014 Mar 7;140(9):094106
pubmed: 24606352
Bioorg Med Chem Lett. 2009 Jan 15;19(2):424-7
pubmed: 19062275
J Mol Model. 2013 Jan;19(1):1-32
pubmed: 23187683
J Chem Theory Comput. 2015 Dec 8;11(12):5583-97
pubmed: 26642981
J Med Chem. 2005 Jul 14;48(14):4558-75
pubmed: 15999994
PLoS One. 2016 Sep 12;11(9):e0162491
pubmed: 27618313
J Comput Chem. 2007 Jan 15;28(1):222-37
pubmed: 17109433
J Mol Model. 2019 Apr 6;25(5):114
pubmed: 30955095
J Mol Model. 2020 May 18;26(6):144
pubmed: 32424505
Crit Rev Oncol Hematol. 2011 Nov;80(2):241-56
pubmed: 21035354

Auteurs

Kornelia Czaja (K)

Chair and Department of Organic Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, ul. Grunwaldzka 6, 60-780 Poznań, Poland.

Jacek Kujawski (J)

Chair and Department of Organic Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, ul. Grunwaldzka 6, 60-780 Poznań, Poland.

Paweł Śliwa (P)

Faculty of Chemical Engineering and Technology, Cracow University of Technology, ul. Warszawska 24, 31-155 Kraków, Poland.

Rafał Kurczab (R)

Maj Institute of Pharmacology, Polish Academy of Sciences, ul. Smętna 12, 31-343 Kraków, Poland.

Radosław Kujawski (R)

Chair and Department of Pharmacology, Faculty of Pharmacy, Poznan University of Medical Sciences, ul. Rokietnicka 5a, 60-806 Poznań, Poland.

Anna Stodolna (A)

Chair and Department of Organic Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, ul. Grunwaldzka 6, 60-780 Poznań, Poland.

Agnieszka Myślińska (A)

Chair and Department of Organic Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, ul. Grunwaldzka 6, 60-780 Poznań, Poland.

Marek K Bernard (MK)

Chair and Department of Organic Chemistry, Faculty of Pharmacy, Poznan University of Medical Sciences, ul. Grunwaldzka 6, 60-780 Poznań, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH